Details

Autor(en) / Beteiligte

• Xu, Ruihan
• Du, Shiyao
• Zhu, Junmeng
• Meng, Fanyan
• Liu, Baorui

Titel

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

Ist Teil von

• Cancer letters, 2022-10, Vol.546, p.215840-215840, Article 215840

Ort / Verlag

Clare: Elsevier B.V

Erscheinungsjahr

2022

Quelle

ScienceDirect journals Piacenza

Beschreibungen/Notizen

• T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive. However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges. Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review. •Neoantigen-targeted TCR-T cell therapy is one of the most promising immunotherapies for solid tumors.•Neoantigen-targeted TCR-T cell therapy has good safety and efficacy.•The timely and effective identification of neoantigens is still the main obstacle to personalized tumor immunotherapy.•The establishment of a shared neoantigen TCR library shortens the time of neoantigen identification.